Global Recombinant Vector Vaccines Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Vector Vaccines Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
Recombinant Vector Vaccines report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Vector Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from For Adult and For Child are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Vector Vaccines industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Vector Vaccines key manufacturers include SANOFI PASTEUR S.A., Novartis, GSK, CNBG, ChengDa Bio, Changsheng Life, Zhifei, SINOVAC BIOTECH and NuoCheng Bio, etc. SANOFI PASTEUR S.A., Novartis, GSK are top 3 players and held % sales share in total in 2022.
Recombinant Vector Vaccines can be divided into Varicella, Influenza, Polio and Hepatitis A, etc. Varicella is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Vector Vaccines is widely used in various fields, such as For Adult and For Child, etc. For Adult provides greatest supports to the Recombinant Vector Vaccines industry development. In 2022, global % sales of Recombinant Vector Vaccines went into For Adult filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Vector Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
SANOFI PASTEUR S.A.
Novartis
GSK
CNBG
ChengDa Bio
Changsheng Life
Zhifei
SINOVAC BIOTECH
NuoCheng Bio
Hualan Bio
Kangtai
Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, tetanus
Pneumococcal
Others
For Adult
For Child
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Vector Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Vector Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Vector Vaccines industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Vector Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Vector Vaccines introduction, etc. Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Vector Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
Recombinant Vector Vaccines report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Vector Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from For Adult and For Child are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Vector Vaccines industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Vector Vaccines key manufacturers include SANOFI PASTEUR S.A., Novartis, GSK, CNBG, ChengDa Bio, Changsheng Life, Zhifei, SINOVAC BIOTECH and NuoCheng Bio, etc. SANOFI PASTEUR S.A., Novartis, GSK are top 3 players and held % sales share in total in 2022.
Recombinant Vector Vaccines can be divided into Varicella, Influenza, Polio and Hepatitis A, etc. Varicella is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Vector Vaccines is widely used in various fields, such as For Adult and For Child, etc. For Adult provides greatest supports to the Recombinant Vector Vaccines industry development. In 2022, global % sales of Recombinant Vector Vaccines went into For Adult filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Vector Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
SANOFI PASTEUR S.A.
Novartis
GSK
CNBG
ChengDa Bio
Changsheng Life
Zhifei
SINOVAC BIOTECH
NuoCheng Bio
Hualan Bio
Kangtai
Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, tetanus
Pneumococcal
Others
Segment by Application
For Adult
For Child
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Vector Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Vector Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Vector Vaccines industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Vector Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Vector Vaccines introduction, etc. Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Vector Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.